# A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease

Clinical trial · Energenesis Biomedical Co., Ltd.

- Archive id: nct:NCT07647614
- Published: 2026-06-15
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07647614
- Source URL: https://clinicaltrials.gov/study/NCT07647614
- Provenance: clinicaltrials

## Abstract

The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications. The main question it aims to answer is: Does ENERGI-F705 Tablets work to treat Parkinson's disease when used with standard-of-care treatment? Investigators will compare the three treatment groups, high-dose ENERGI-F705 Tablets (120 milligrams twice daily), low-dose ENERGI-F705 Tablets (60 milligrams twice daily), and placebo tablets (a look-alike substance that contains no drug), to see if ENERGI-F705 Tablets work to treat Parkinson's disease. Participants will: \* Take the study drugs twice a day for 72 weeks in the treatment group \* Take routine use of standard-of-care antiparkinsonian medications throughout the study \* Visit the outpatient department at scheduled visits, ranging from Day 1 to approximately every 1 to 4 weeks thereafter, for checkups and tests

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: NOT_YET_RECRUITING
- phase: PHASE2
- study type: INTERVENTIONAL
- enrollment: 105
- sponsor: Energenesis Biomedical Co., Ltd.
- conditions: Parkinson's Disease (PD)
- interventions: DRUG: 60 milligrams of ENERGI-F705 Tablets; DRUG: Placebo tablets; DRUG: 120 milligrams of ENERGI-F705 Tablets
- start date: 2026-12-01
- start date type: ESTIMATED
- primary completion date: 2030-01-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Alzheimer's, Parkinson's & Neurodegeneration](https://space-kitty.com/topics/neurodegeneration)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.